newsfilter
← Latest News
GlobeNewswire·

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights

Delivered record full-year total revenue and AVISE CTD average selling priceImproved full-year adjusted EBITDA loss and cash use by over 40%Commercialized new biomarkers to enhance clinical utility of AVISE CTD